PTC Therapeutics Starts Phase 2 Trials on PTC299
PTC299 is an orally administered drug developed by PTC Therapeutics. They are looking for people with NF2 to participate in in the next phase of clinical trials.
August 5th, 2009
This entry was posted on Wednesday, August 5th, 2009 at 9:07 am and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.
